A 45-year-old woman had refractory Epstein–Barr virus-associated gastroparesis. Despite lifestyle modification and medication therapy, the patient had recurrent hospitalizations for gastroparesis. Management also included four previous sessions of endoscopic botulinum toxin injection. Despite transient symptomatic improvement, the patient’s symptoms had recurred. She was not a candidate for surgical implantation of a gastric pacemaker, so she was referred for gastric peroral endoscopic myotomy (G-POEM).

During the procedure (Video 1), a submucosal bleb was created with a methylene blue and saline solution, 6 cm proximal to the gastroesophageal junction. A mucosal entry point was incised with a multipurpose knife and an endoscope was advanced into the submucosa. The submucosal space was dissected using intermittent injection and dissection with spray coagulation current. In patients who have not undergone previous botulinum toxin injection, injection of the submucosa will facilitate separation between the mucosa and muscle layers (Fig. 1) However, this patient’s submucosal tunnel demonstrated significant scarring. The botulinum toxin caused areas of fusion of the mucosa and the muscularis with dense scarring and opaque submucosa leading to a more challenging dissection (Video 1).

Once the submucosal tunnel was dissected down to the pylorus level, pyloromyotomy was performed. The submucosal tunnel was washed with topical liquid gentamicin, and the mucosal entry site was closed using multiple endoscopic sutures.

At 3 months’ follow-up, the patient has regained a normal quality of life with weight gain of 10 kg.

G-POEM is a novel endoscopic therapy for refractory gastroparesis, that involves mucosal entry, submucosal tunneling, pyloromyotomy, and closure of the mucosal entry site. It is associated with an 86% symptomatic improvement in patients with refractory gastroparesis [1]. Previous endoscopic botulinum toxin injection is associated with a more challenging submucosal tunneling (Fig. 1). Recent studies recommend against endoscopic botulinum toxin injection for gastroparesis [2–4]. Video 1 highlights the submucosal fibrosis secondary to botulinum toxin injection that leads to a more challenging dissection during G-POEM.

Endoscopy_UCTN_Code_TTT_1AO_2AN
Competing interests

Michel Kahaleh MD: has received grant support from Boston Scientific, Fujinon, EMcision, Xlumena Inc., W.L. Gore, MaunaKea, Apollo Endosurgery, Cook Endoscopy, ASPIRE Bariatrics, GI Dynamics, NinePoint Medical, Merit Medical, Olympus and Mi Tech. He is a consultant for Boston Scientific, Xlumena Inc., Concordia Laboratories Inc, ABBvie, and MaunaKea Tech. All other authors have no conflicts of interest to report.

The Authors

Monica Saumoy1, Najib Nassani1, Joaquin Ortiz2, Viviana Parra3, Amy Tyberg1, Michel Kahaleh1

1 Division of Gastroenterology and Hepatology New York Presbyterian Hospital, Weill Cornell Medical College, New York, United States
2 Instituto Nacional de Cancerologia, Delegacion Tlalpan, Mexico City, Mexico
3 Clinica Universitaria Columbia, Bogota, Colombia

Corresponding author

Michel Kahaleh, MD
1305 York Ave, 4th Floor, New York, NY 10021, United States
Fax: 01-646-962-0110
mkahaleh@gmail.com

References